Skip to content Skip to footer
Subscribe Now
NEWS

Innovent and Eli Lilly Strike ~$8.85B ex-China Collaboration to Accelerate Oncology & Immunology Programs

Shots: Innovent & Eli Lilly have entered into a strategic collaboration to advance novel medicines in oncology & immunology As per the deal, Innovent will advance the programs from discovery through P-II PoC trial in China using its antibody platforms, while Lilly will receive exclusive rights to develop & commercialize the assets globally, excl. Greater…
February 9, 2026

Read more

NEWS

Saya Biologics and Kashiv BioSciences Partner to Introduce a Biosimilar Supportive Oncology Therapy in Mexico and the CAC Region 

Shots:  Saya Biologics has signed a strategic partnership with Kashiv BioSciences to register and commercialize a supportive oncology therapy in Mexico and the CAC region  As per the deal, the agreement spans 11 countries across Mexico and the CAC region. Saya Biologics will handle regulatory registration, commercialization, and distribution, while Kashiv BioSciences will oversee manufacturing and supply.   Saya has already submitted the regulatory dossier in Mexico,…
February 4, 2026

Read more

NEWS

Origami Therapeutics Collaborates with Ipsen to Develop Protein Degrader Program for Neurodegenerative Disorder

Shots: Origami Therapeutics has entered into a global collaboration & option agreement with Ipsen to develop a small-molecule protein degrader, using Origami’s Oricision platform, for a rare inherited neurodegenerative disorder Under the deal, Ipsen will secure an exclusive option to license the program globally after drug candidate nomination &, upon exercise, would take over worldwide…
February 2, 2026

Read more

NEWS

CSPC Pharmaceutical and AstraZeneca Seal ~$18.5B Long-Acting Peptide Deal for Obesity

Shots: CSPC has entered a strategic collaboration & license deal with AZ to develop long-acting peptides, using CSPC’s sustained-release delivery tech platform & AI-driven peptide drug discovery platform As per the deal, the Group will collaborate with AZ on novel peptide discovery & long-acting delivery, while AZ will gain exclusive global rights (excl. Greater China)…
January 30, 2026

Read more

NEWS

Recordati and Moderna Collaborate To Develop And Commercialize mRNA 3927 in a ~$160M Deal

Shots: Recordati has entered into a collaboration & license deal with Moderna to develop & commercialize mRNA-3927 globally for the treatment of propionic acidemia As per the deal, Moderna will continue to co-develop mRNA-3927 with Recordati, while Recordati will lead global commercialization if approved. In exchange, Moderna will receive $50M upfront, ~$110M in development &…
January 30, 2026

Read more

NEWS

Repertoire Immune Medicines and Eli Lilly Enter ~$1.9B Deal to Develop Tolerizing Therapies for Autoimmune Diseases

Shots: Repertoire has entered into a strategic collaboration with Eli Lilly to develop tolerizing therapies for multiple autoimmune diseases Repertoire will use its DECODE TCR–epitope discovery platform to identify candidates & lead collaboration activities through nomination, after which Lilly will oversee clinical development, manufacturing, regulatory activities, & commercialization Under the terms, Repertoire will receive $85M…
January 29, 2026

Read more

NEWS

Seamless Therapeutics and Eli Lilly Forge ~$1.12B Deal to Develop Hearing Loss Therapies

Shots: Seamless has entered into a strategic global research collaboration & licensing deal with Eli Lilly to develop & commercialize programmable recombinase-based therapies for hearing loss using Seamless’ proprietary recombinase platform Under the deal, Seamless will design site-specific recombinases to correct hearing-loss–related gene mutations, while Lilly will receive an exclusive license to advance these programmed…
January 29, 2026

Read more

NEWS

Boehringer Ingelheim and Simcere Pharmaceutical ~$1.26B Deal to Develop SIM0709

Shots: Boehringer Ingelheim and Simcere have entered a license and collaboration agreement to develop SIM0709, a preclinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD) As per the deal, Boehringer Ingelheim gains global rights to the asset excluding Greater China, while Simcere is eligible for an upfront payment, milestones up to €1.058B…
January 28, 2026

Read more

NEWS

Janux Therapeutics and BMS Forge ~$850M Deal to Develop Therapies in Oncology

Shots: Janux has entered into a collaboration & exclusive global license agreement with BMS to develop a novel, undisclosed tumor-activated therapy targeting a validated solid-tumor antigen expressed across multiple cancer types Janux will advance the program through preclinical development & IND submission, after which BMS will hold the IND, lead global development & commercialization, with…
January 23, 2026

Read more

NEWS

Insilico Medicine and Hygtia Therapeutics Partner to Advance ISM8969 for CNS Disorders

Shots: Insilico Medicine & Hygtia Therapeutics have entered into a co-development global collaboration agreement for Insilico's ISM8969 program for CNS disorders As per the deal, Hygtia will receive 50% worldwide rights to research, develop, register, manufacture, & commercialize ISM8969 in exchange for ~$66M, incl. milestone payments & $10M initial upfront payment Under the agreement, Insilico…
January 21, 2026

Read more

Load more